Fez1/Lzts1 a new mitotic regulator implicated in cancer development.
Considerable evidence has accumulated suggesting that cancer has genetic origin, based on the development of genomic alterations, such as deletions, mutations, and/or methylations in critical genes for homeostasis of cellular functions, including cell survival, DNA replication and cell cycle control. Mechanism controlling the precise timing and sequence of cell cycle events as well as checkpoints insuring fidelity of those events are key targets that when disrupted could result in tumorigenesis. Mitosis is the process by which a cell duplicates its genetic information (DNA), in order to generate two, identical, daughter cells. In addition each daughter cell must receive one centrosome and the appropriate complements of cytoplasm and organelles. This process is conventionally divided in to five distinct stages: prophase, prometaphase, metaphase, anaphase and telophase that correspond to a different morphology of the cell. The entry into mitosis (M) is under the control of the cyclin dependent kinase Cdk1. During G2, the kinases Wee1 and Myt1 phosphorylate Cdk1 at T14/Y15 residues, rendering it inactive. The transition from G2 to M is promoted by the activation of Cdk1 via dephosphorylation by the Cdk1 phosphatase Cdc25C. Activated Cdk1 complexes translocate into the nucleus during prophase where phosphorylate numerous substrates in order to enhance their activation as the cells progresses trough prophase, prometaphase, and metaphase.Recently we identified a new player: FEZ1/LZTS1 that contributes to the fine-tuning of the molecular events that determine progression through mitosis, and here will review its role in cancer development and in M phase regulation.
Vecchione
Andrea
A
Department of Molecular Virology, Immunology and Medical Genetics and Comprehensive Cancer Center, Ohio State University, OH, USA. carlo.croce@osumc.edu.
Croce
Carlo M
CM
Baldassarre
Gustavo
G
Oncogene. 2001 Oct 11;20(46):6707-17
11709705
Clin Cancer Res. 2001 Jun;7(6):1546-52
11410489
Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3928-33
10097140
Clin Cancer Res. 2002 Jul;8(7):2292-7
12114433
Oncol Rep. 2005 Aug;14(2):547-51
16012743
Nat Rev Mol Cell Biol. 2001 Jan;2(1):21-32
11413462
Oncogene. 2001 Jul 12;20(31):4169-79
11464283
Biochim Biophys Acta. 2001 May 28;1519(1-2):1-12
11406266
Mol Cell Biol. 2006 Dec;26(23):8857-67
17000760
Int J Oncol. 2003 Aug;23(2):297-302
12851677
BMC Urol. 2004 Sep 9;4:11
15357873
Cancer Res. 2005 Feb 15;65(4):1207-12
15735004
Cancer Cell. 2007 Mar;11(3):275-89
17349584
Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10374-9
11504921
Cancer Genet Cytogenet. 2002 Aug;137(1):1-7
12377406
Am J Pathol. 2002 Apr;160(4):1345-52
11943719
Trends Cell Biol. 2006 Jan;16(1):55-63
16337124
Biochemistry. 2007 Mar 27;46(12):3595-604
17328562
Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):1990-5
11842186